Is Retatrutide approved or legal?

No. As of mid-2026 retatrutide is an investigational drug developed by Eli Lilly and is not approved by the FDA, EMA, or any major regulator. It is in phase 3 trials (TRIUMPH program). Any material sold outside clinical trials is unregulated and labeled research-use-only, not for human consumption.

What is the half-life and how often is it dosed?

Retatrutide has a half-life of roughly 6 days due to reversible albumin binding from its fatty-diacid modification, which supports once-weekly subcutaneous dosing. Steady-state plasma levels are typically reached after about 4-5 weeks.

How much weight loss did retatrutide produce in trials?

In the 48-week phase 2 obesity trial, the 12 mg dose produced a mean weight reduction of about 24.2%, with dose-dependent results at lower doses. The phase 3 TRIUMPH program is ongoing with readouts expected in 2026; these are clinical-trial results, not guarantees for any individual.

How does retatrutide differ from tirzepatide or semaglutide?

Semaglutide is a single GLP-1 agonist and tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds a third target - the glucagon receptor - which is hypothesized to increase energy expenditure and hepatic fat mobilization, and may contribute to its larger trial weight-loss magnitude.

Metabolic

Retatrutide

Also known as: LY3437943

Investigational once-weekly triple agonist (GIP/GLP-1/glucagon) by Eli Lilly; phase 2 data show large weight loss. Not approved.

Last updated July 11, 2026

Reconstitute this peptide Buy Retatrutide

Overview

Retatrutide (LY3437943) is an investigational, once-weekly injectable peptide developed by Eli Lilly. It is a first-in-class "triple agonist" that simultaneously activates the GIP, GLP-1, and glucagon receptors. The glucagon-receptor component is the main feature distinguishing it from dual agonists like tirzepatide, and is thought to add an energy-expenditure effect on top of appetite suppression. In a 48-week phase 2 obesity trial (NEJM, 2023), the highest 12 mg dose produced a mean weight reduction of about 24.2%, among the largest reductions reported for any pharmacologic obesity agent in trials to date. A separate phase 2a trial showed marked reductions in liver fat in people with metabolic dysfunction-associated steatotic liver disease (MASLD). Eli Lilly's phase 3 TRIUMPH program is ongoing. As of mid-2026, retatrutide is NOT approved by the FDA, EMA, or any major regulator and remains an experimental compound under clinical investigation. Material sold by research-chemical vendors is unregulated, not pharmaceutical-grade, and is labeled research-use-only. The data below summarizes published evidence and clearly separates clinical findings from anecdotal community use.

How it works

Retatrutide is a single synthetic peptide that agonizes three incretin/metabolic receptors: GIP, GLP-1, and glucagon. GLP-1 and GIP agonism enhance glucose-dependent insulin secretion and promote satiety/slowed gastric emptying (reducing food intake), while glucagon-receptor agonism is proposed to increase energy expenditure and hepatic fat mobilization. A C20 fatty-diacid moiety promotes reversible binding to serum albumin, creating a depot effect that extends the half-life and supports once-weekly dosing. The combined appetite-suppression plus energy-expenditure mechanism is the leading hypothesis for its observed weight-loss magnitude, though the relative contribution of each receptor in humans is not fully resolved.

Researched effects

Clinical Substantial body-weight reduction (up to ~24% mean at 12 mg over 48 weeks in the phase 2 obesity trial)
Clinical Improved glycemic control and metabolic parameters in adults with obesity/overweight
Clinical Large dose-dependent reductions in liver fat (MASLD), with many high-dose participants reaching normal liver-fat levels at 24 weeks in a phase 2a trial
Preclinical Potential attenuation of obesity-associated cancer progression
Anecdotal Community reports of strong appetite suppression and rapid weight loss at sub-clinical 'microdoses'

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

In Eli Lilly trials, retatrutide is given as a once-weekly subcutaneous injection with stepwise dose escalation to limit GI side effects. The phase 2 obesity trial used maintenance doses of 1, 4, 8, and 12 mg weekly, titrated upward over the first ~12-16 weeks (e.g., starting around 2-4 mg and increasing every 2-4 weeks). The largest weight loss occurred at 8-12 mg. These are investigational protocols; retatrutide has no approved label or established clinical dosing for general use.

Community-reported dosing (anecdotal)

ANECDOTAL / RESEARCH-REFERENCE ONLY - not medical advice and not an instruction to dose. Online peptide forums and Reddit communities (e.g., r/Peptides) report self-experimentation with research-grade material that broadly mirrors the trial titration logic: conservative starts around 0.5-2 mg once weekly, escalating slowly (often every 2-4 weeks) toward 4-12 mg based on tolerance. A common community pattern is 'microdosing' - splitting the weekly amount into two or three smaller injections (e.g., twice weekly) in an attempt to flatten peak concentrations and reduce nausea; this is based on pharmacokinetic reasoning and personal experience, NOT on any controlled trial. Reported themes include strong GI side effects when escalating too fast and noticeable heart-rate increases. These protocols are unverified, use unregulated product, and should not be treated as safe or validated.

Half-life: ~6 days (supports once-weekly dosing; steady state in ~4-5 weeks)
Routes: subcutaneous

Safety & side effects

The most common adverse events in trials are gastrointestinal - nausea, vomiting, diarrhea, and constipation - which are dose-dependent, mostly mild-to-moderate, and concentrated during dose escalation; a lower starting dose and slower titration reduce them. Dose-dependent increases in heart rate (roughly 5-10 bpm) have been observed. Trial discontinuations due to adverse events ranged from about 6-16% across retatrutide arms. Through 48 weeks no hepatotoxicity signal was reported in the MASLD substudy, and no ketoacidosis occurred despite mild increases in ketone markers. As a glucagon-receptor agonist, blood-glucose effects warrant monitoring, particularly with concurrent diabetes medication. Long-term safety, cardiovascular outcomes, and effects of unregulated research-grade product are unknown. Class cautions for incretin agonists include pancreatitis, gallbladder issues, and a theoretical thyroid C-cell tumor signal seen in rodents. Not for use in pregnancy. Research-use-only; not approved for human consumption.

Research summary

Retatrutide has the strongest clinical evidence base of the emerging next-generation metabolic peptides short of approval. The pivotal published data is the 2023 NEJM phase 2 obesity trial, in which once-weekly subcutaneous dosing produced dose-dependent weight loss reaching a mean of ~24.2% at the 12 mg dose over 48 weeks - exceeding what dual agonists achieved at comparable timepoints. A phase 2a MASLD trial showed large, dose-dependent reductions in liver fat, with the majority of high-dose participants normalizing liver fat by 24 weeks and no hepatotoxicity signal. A 2025 systematic review/meta-analysis of randomized trials confirmed significant weight and metabolic benefits with an adverse-event profile dominated by transient GI effects. The leading mechanistic hypothesis is that adding glucagon-receptor agonism to GLP-1/GIP activity layers increased energy expenditure and hepatic fat mobilization on top of appetite suppression, which may explain the larger weight-loss magnitude. However, human dose-response across the three receptors is incomplete, and cardiovascular outcome data are not yet available. The phase 3 TRIUMPH program (including type 2 diabetes and cardiovascular-disease populations) is ongoing, with key readouts expected in 2026. The central honest caveat is regulatory status: retatrutide is investigational and unapproved everywhere as of mid-2026. Material available outside trials is unregulated research chemical of unverified identity, purity, and sterility. Community/Reddit dosing accounts are anecdotal, often involve such material, and should be read as research reference only - not as evidence of safety, efficacy, or appropriate self-administration.

FAQ

Is Retatrutide approved or legal?: No. As of mid-2026 retatrutide is an investigational drug developed by Eli Lilly and is not approved by the FDA, EMA, or any major regulator. It is in phase 3 trials (TRIUMPH program). Any material sold outside clinical trials is unregulated and labeled research-use-only, not for human consumption.
What is the half-life and how often is it dosed?: Retatrutide has a half-life of roughly 6 days due to reversible albumin binding from its fatty-diacid modification, which supports once-weekly subcutaneous dosing. Steady-state plasma levels are typically reached after about 4-5 weeks.
How much weight loss did retatrutide produce in trials?: In the 48-week phase 2 obesity trial, the 12 mg dose produced a mean weight reduction of about 24.2%, with dose-dependent results at lower doses. The phase 3 TRIUMPH program is ongoing with readouts expected in 2026; these are clinical-trial results, not guarantees for any individual.
What are the main side effects?: The most common are dose-dependent gastrointestinal effects (nausea, vomiting, diarrhea, constipation), mostly mild-to-moderate and concentrated during dose escalation. A modest heart-rate increase (~5-10 bpm) has also been observed. Slower titration tends to reduce GI effects.
How does retatrutide differ from tirzepatide or semaglutide?: Semaglutide is a single GLP-1 agonist and tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds a third target - the glucagon receptor - which is hypothesized to increase energy expenditure and hepatic fat mobilization, and may contribute to its larger trial weight-loss magnitude.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.